Abeona Therapeutics Inc. (ABEO) Stock Analysis

Abeona Therapeutics® Congratulates Ultragenyx on U.S. FDA Approval of FAYUVI™ Gene Therapy for Sanfilippo Syndrome Type A (MPS IIIA)

Fri, September 18, 2026 at 11:30 AM UTC 2 min read

Abeona Therapeutics congratulated Ultragenyx on the U.S. FDA approval of FAYUVI™, a gene therapy for Sanfilippo Syndrome Type A. This approval underscores the growing interest and advancements in gene therapies, which could positively influence investor sentiment in the sector. While this news directly pertains to Ultragenyx, it highlights the competitive landscape in rare disease treatments, potentially impacting Abeona's market position and future collaborations.

Read full article →

ABEO Stock Gains On Approval For A Drug Abeona Sold, Rating For The One It Sells

Thu, September 17, 2026 at 11:33 PM UTC 4 min read

ABEO's stock experienced gains following the approval of a drug that was previously sold by Abeona Therapeutics. This development is significant for investors as it highlights the potential for revenue generation from approved therapies, enhancing ABEO's market position and future growth prospects. The positive momentum may also attract investor interest, reflecting confidence in the company's pipeline and strategic direction.

Read full article →